Related Experiment Video

Updated: Aug 13, 2026

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
12:58

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Published on: May 10, 2017

Expression of Fas ligand in newly diagnosed childhood acute lymphoblastic leukemia

M Volm1, F Zintl, A Sauerbrey

  • 1German Cancer Research Center, Department of Oncological Diagnostics and Therapy, Heidelberg, Germany.

Anticancer Research
|January 12, 2000
PubMed

Insights

Fas ligand (FasL) expression in children with acute lymphoblastic leukemia (ALL) is linked to better survival outcomes. This suggests Fas/FasL signaling enhances chemotherapy effectiveness in treating childhood ALL.

Area of Science:

  • Pediatric Oncology
  • Immunology
  • Molecular Biology

Background:

  • Acute lymphoblastic leukemia (ALL) is a common childhood cancer.
  • Understanding molecular markers that predict treatment response is crucial for improving outcomes.

Purpose of the Study:

  • To investigate the expression of Fas ligand (FasL) in children with newly diagnosed ALL.
  • To determine the correlation between FasL expression and patient survival in childhood ALL.

Main Methods:

  • Immunocytochemistry was employed to detect FasL expression.
  • Sixty-four children with newly diagnosed ALL were analyzed.
  • Relapse-free and overall survival rates were compared based on FasL expression status.

Main Results:

  • FasL expression was observed in 86% (55 of 64) of children with newly diagnosed ALL.
  • Children with ALL and FasL expression demonstrated significantly longer relapse-free and overall survival times during chemotherapy.
  • Patients lacking FasL expression had poorer survival outcomes.

Conclusions:

  • FasL expression is a prevalent marker in newly diagnosed childhood ALL.
  • The presence of FasL correlates with improved survival, suggesting a favorable prognostic role.
  • Fas/FasL-mediated signaling may enhance the cytotoxic effects of anticancer drugs in ALL treatment.

More Related Videos

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation09:09

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Published on: November 10, 2017

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Related Concept Videos

Proliferative Phase01:20

Proliferative Phase

The proliferative phase typically occurs after menstruation and lasts between 6 to 13 days in a standard 28-day cycle. This phase involves the reconstruction of the endometrium, guided by estrogen produced by the developing ovarian follicle.
Notably, the stratum basale, the basal layer of the endometrium, including the basal parts of the uterine glands, remains unaffected by menstruation. Stem cells in this layer undergo mitosis, regenerating the stratum functionalis and thickening the...